A mixture of MSM, kombucha, and black tea was applied topically for hair growth in mice. The conversation suggests skepticism about translating these results to humans.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
After a hair transplant, it's advised to stop using RU58841 and minoxidil to avoid irritation, resuming them 25-30 days post-surgery if the scalp is healed. The user is currently using finasteride, minoxidil, and RU58841, but there are concerns about the safety and efficacy of RU58841 in humans.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
Adipose-derived stemcells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stemcells with ATP for males and medium dose stemcells with non-liposomal ATP for females.
A new hair growth product claims to use apple stemcells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.
Dutasteride may be better for the brain than Finasteride, potentially increasing dopamine levels and causing fewer side effects. For those switching from Finasteride to Dutasteride to prevent hair loss, it's recommended to continue Finasteride for 3-4 months while starting Dutasteride to avoid shedding due to Dutasteride's long half-life.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
A breakthrough in hair follicle cultivation using induced pluripotent stemcells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.
Stem cell hair transplants use stemcells from fat tissue to reactivate inactive hair follicles, but results are inconsistent and not widely shared. Traditional treatments like finasteride and minoxidil often show better results.
Hair follicle stemcells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
There is concern about a potential ban on finasteride and dutasteride in the EU, with users discussing the impact on hair loss treatment. Some suggest alternative treatments or express skepticism about the likelihood of a ban.
There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
This conversation is a humorous discussion about the effects of Minoxidil and Finasteride on hair growth, with some users speculating that it may have turned the poster into a "scientific horror story".
The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.
Stem cell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stemcells could potentially offer a more permanent solution.
User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
Finasteride and Dutasteride do not cause dry eyes by damaging meibomian glands, as these glands continue to function normally even when DHT is blocked. Some users report dry eyes with these medications, but others suggest supplements like Omega-3 or krill oil as potential remedies.
Hair loss is linked to the loss of stemcells in hair follicles, and potential treatments include gene editing and microneedling. Discussions also mention using Minoxidil, finasteride, and dermarolling to improve hair growth.